Efficacy of folic acid and enalapril combined therapy on reduction of blood pressure and plasma glucose: A multicenter, randomized, double-blind, parallel-controlled, clinical trial

Nutrition

Volumn 24, Issue 11-12, 2008, Pages 1088-1096

  Mao, Guangyun ^a   Hong, Xiumei ^b   Xing, Houxun ^a   Liu, Ping ^a   Liu, Haipeng ^c   Yu, Yunxian ^b   Zhang, Shanchun ^b   Jiang, Shanqun ^a   Wang, Xiaobin ^b   Xu, Xiping ^a,d  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b CHILDREN'S MEMORIAL HOSPITAL   (United States)

^c UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Chinese; Enalapril; Folic acid; Hyperglycemia; Hypertension; Randomized clinical trial

Indexed keywords

ENALAPRIL; FOLIC ACID; GLUCOSE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ENALAPRIL; FASTING; FEMALE; FOLIC ACID; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; LINEAR MODELS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 53449094759     PISSN: 08999007     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nut.2008.05.009     Document Type: Article

References (35)

1. World Health Organization. Obesity and overweight. http://www.who.int/dietphysicalactivity/publications/facts/obesity/en/ Accessed September 21, 2006
2. Hu G., Sarti C., Jousilahti P., Peltonen M., Qiao Q., Antikainen R., and Tuomilehto J. The impact of history of hypertension and type 2 diabetes at baseline on the incidence of stroke and stroke mortality. Stroke 36 (2005) 2538-2543
3. Bosch J., Yusef S., Gerstein H.C., Pogue J., Sheridan P., Dagenais G., et al. Effect of ramipril on the incidence of diabetes. N Engl J Med 355 (2006) 1551-1562
4. Hansson L., Lindholm L.H., Niskanen L., Lanke J., Hedner T., Niklason A., et al. Effects of angiotensin converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 353 (1999) 611-616
5. Yusuf S., Gerstein H., Hoogwerf B., Pogue J., Bosch J., Wolffenbuttel B.H., and Zinman B. Ramipril and the development of diabetes. JAMA 286 (2001) 1882-1885
6. Padwal R., Majumdar S.R., Johnson J.A., Varney J., and McAlister F.A. A systematic review of drug therapy to delay or prevent type 2 diabetes. Diabetes Care 28 (2005) 736-744
7. Kjeldsen S.E., Julius S., Mancia G., McInnes G.T., Hua T., Weber M.A., et al. Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. J hypertens 24 (2006) 1405-1412
8. Sacco R.L., Adams R., Albers G., Alberts M.J., Benavente O., Furie K., et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack. Stroke 37 (2006) 577-617
9. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288 (2002) 2981-2997
10. Lip G.Y., Edmunds E., Martin S.C., Jones A.F., Blann A.D., and Beevers D.G. A pilot study of homocysteine levels in essential hypertension: relationship to von Willebrand factor, an index of endothelial damage. Am J Hypertens 14 (2001) 627-631
11. Sutton-Tyrrell K., Bostom A., Selhub J., and Zeigler-Johnson C. High homocysteine levels are independently related to isolated systolic hypertension in older adults. Circulation 96 (1997) 1745-1749
12. Meigs J.B., Jacques P.F., Selhub J., Singer D.E., Nathan D.M., Rifai N., et al., Framingham Offspring Study. Fasting plasma homocysteine levels in the insulin resistance syndrome. Diabetes Care 24 (2001) 1403-1410
13. Gillum R. Distribution of serum total homocysteine and its association with diabetes and cardiovascular risk factors of the insulin resistance syndrome in Mexican American men: the Third National Health and Nutrition Examination Survey. Nutr J 2 (2003) 6-13
14. Wang X., Qin X., Demirtas H., Li J., Mao G., Huo Y., et al. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet 369 (2007) 1876-1882
15. Najib S., and Sanchez-Margalet V. Homocysteine thiolactone inhibits insulin signaling. Protective effect of glutathione. J Mol Endocrinol 27 (2001) 85-91
16. Moat S.J., Lang D., McDowell I.F., Clark Z.L., Madhavan A.K., Lewis M.J., and Goodfellow J. Folate, homocysteine, endothelial function and cardiovascular disease. J Nutr Biochem 15 (2004) 64-79
17. Homocysteine Lowering Trialists' Collaboration. Dose dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials. Am J Clin Nutr 82 (2005) 806-812
18. Ubbink J.B., Hayward-Vermaak W.J., and Bissbort S. Rapid high-performance liquid chromatographic assay for total homocysteine levels in human serum. J Chromatogr 565 (1991) 441-446
19. Gu D.F., He J., Duan X.F., et al. Main causes and its modifiable risks of death among men and women in China. Chin J Prev Chron Noncommun Dis 14 (2006) 149-154
20. Vermes E., Ducharme A., Bourassa M.G., Lessard M., White M., and Tardif J.-C. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation 107 (2003) 1291-1296
21. Dahlöf B., Sever P.S., Poulter N.R., Wedel H., Beevers D.G., Caulfield M., et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOTBPLA):a multicentre randomized controlled trial. Lancet 366 (2005) 895-906
22. Yusef S., Sleight P., Pogue J., Bosch J., Davies R., and Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342 (2000) 145-153
23. Dagenais G.R., Pogue J., Fox K., Simoons M.L., and Yusuf S. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combine analysis of three trial. Lancet 368 9535 (2006) 581-588
24. Tillmann H.C., Walker R.J., Lewis-Barned N.J., Edwards E.A., and Robertson M.C. A long-term comparison between enalapril and captopril on insulin sensitivity in normotensive non-insulin dependent diabetic volunteers. J Clin Pharm Ther 22 (1997) 273-278
25. Wing L.M.H., Reid C.M., Ryan P., Beilin L.J., Brown M.A., Jennings G.L., et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 348 (2003) 583-592
26. Taylor E.N., Hu F.B., and Curhan G.C. Antihypertensive medications and the risk of incident type 2 diabetes. Diabetes Care 29 (2006) 1065-1070
27. Kinoshita M., Nakaya Y., Harada N., Takahashi A., Nomura M., and Bando S. Combination therapy of exercise and angiotensin-converting enzyme inhibitor markedly improves insulin sensitivities in hypertensive patients with insulin resistance. Cir J 66 (2002) 655-658
28. Büttner R., Wobser H., Wrede C., Schäffler A., Schölmerich H., Büchler C., and Bollheimer L.C. Supplementation of folic acid improves insulin resistance in the high fat fed rat. Exp Clin Endocrinol Diabetes 115 (2007) doi:10.1055/s-2007-972467
29. Solini A., Santini E., and Ferrannini E. Effect of short-term folic acid supplementation on insulin sensitivity and inflammatory markers in overweight subjects. Int J Obesity 30 (2006) 1197-1202
30. Setola E., Monti L.D., Galluccio E., Palloshi A., Fragasso G., Paroni R., et al. Insulin resistance and endothelial function are improved after folate and vitamin B12 therapy in patients with metabolic syndrome: relationship between homocysteine levels and hyperinsulinemia. Eur J Endocrinol 151 (2004) 483-489
31. Piatti P.M., Di Mario C., Monti L.D., Fragasso G., Sgura F., Caumo A., et al. Association of insulin resistance, hyperinsulinemia, and impaired nitric oxide release with in-stent restenosis in patients undergoing coronary stenting. Circulation 108 (2003) 2074-2081
32. Mangoni A.A., Sherwood R.A., Swift C.G., and Jackson S.H. Folic acid enhances endothelial function and reduces blood pressure in smokers: a randomized controlled trial. J Intern Med 252 (2002) 497-503
33. Nivanjan S., Adrian W., Messerli A.W., Gregory L., et al. Association of elevated plasma total homocysteine levels with hypertension. Am J Hypertens 16 (2003) 248A doi:50895-7061(03)00753-2
34. Henderson D.C., Copeland P.M., Nguyen D.D., Borba C.P., Cather C., Eden Evins A., et al. Homocysteine levels and glucose metabolism in non-obese, non-diabetic chronic schizophrenia. Acta Psychiatr Scand 113 (2006) 121-125
35. Fonseca V.A., Fink L.M., and Kern P.A. Insulin sensitivity and plasma homocysteine concentrations in nondiabetic obese and normal weight subjects. Atherosclerosis 167 (2003) 105-109